Who founded Tizona Therapeutics, Inc.?

Tizona Therapeutics, Inc. was founded by Vijay K. Kuchroo, Drew Pardoll, Dario Vignali, Jedd Wolchok.

Who are Tizona Therapeutics, Inc.'s investors?

Tizona Therapeutics, Inc.'s investors include Canaan Partners, MPM BioImpact, Abingworth, Gilead Sciences, Astellas Venture Management LLC, Lightstone Ventures.

Tizona Therapeutics, Inc.

6 known investors

Find your way into Tizona Therapeutics, Inc.

Paths you didn't know you had: your email and LinkedIn already hold routes to the Tizona Therapeutics, Inc. team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse. The company has advanced two internally generated immunotherapies into clinical trials and maintains a strategic alliance with Gilead Sciences.

AI & Machine Learning Biotech Healthtech

Founders & leadership

Vijay K. KuchrooScientific Co-Founder & Advisory Board Member

Drew PardollScientific Co-Founder & Advisory Board Member

Dario VignaliScientific Co-Founder & Advisory Board Member

Jedd WolchokScientific Co-Founder & Advisory Board Member

Christine O'BrienChief Executive Officer & Board Member

Courtney BeersChief Scientific Officer

Robert Ilaria, Jr.Chief Medical Officer

Board

Dan SpiegelmanBoard Chair

Investors · 6

Canaan Partners✓ confirmed by Tizona Therapeutics, Inc.Stamford · $500K – $20M

How we know: Canaan Partners's portfolio page · the company's own site · funding news · Not right? Tell us

MPM BioImpact✓ confirmed by Tizona Therapeutics, Inc.Boston · $1M – $15M

How we know: MPM BioImpact's portfolio page · the company's own site · Not right? Tell us

Abingworth✓ confirmed by Tizona Therapeutics, Inc.London · $15M – $30M

How we know: the company's own site · funding news · Not right? Tell us

Gilead Sciences✓ confirmed by Tizona Therapeutics, Inc.Foster City

How we know: the company's own site · Not right? Tell us

Astellas Venture Management LLClisted by Astellas Venture Management LLCSouth San Francisco · $200K – $5M

Lightstone Ventureslisted by Lightstone VenturesPortola Valley

How we know: Lightstone Ventures's portfolio page · funding news · the VCSheet dataset · Not right? Tell us

Founder mafia

2 people who came through Tizona Therapeutics, Inc. went on to found or lead other companies.

Bill GrossmanMember Board Of DirectorsFounded Oncko Pablo J. CagnoniPresident & Chief Executive OfficerFounded Rubius Therapeutics

Related companies · 3

Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.

SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Sionna TherapeuticsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.

Companies working in the same space as Tizona Therapeutics, Inc..

In the news

Tizona Initiates Clinical Development of TTX-080 in Advanced Cancers - BioSpacebiospace.com · Jun 2020

Bay Area's Tizona Therapeutics Emerges from Stealth Mode with $70 Million Total in Financing - BioSpacebiospace.com · Mar 2016

Frequently asked questions

What does Tizona Therapeutics, Inc. do?: Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse. The company has advanced two internally generated immunotherapies into clinical trials and maintains a strategic alliance with Gilead Sciences.
Who founded Tizona Therapeutics, Inc.?: Tizona Therapeutics, Inc. was founded by Vijay K. Kuchroo, Drew Pardoll, Dario Vignali, Jedd Wolchok.
Who are Tizona Therapeutics, Inc.'s investors?: Tizona Therapeutics, Inc.'s investors include Canaan Partners, MPM BioImpact, Abingworth, Gilead Sciences, Astellas Venture Management LLC, Lightstone Ventures.